NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings is moving into diagnostics for orphan diseases and today announced it has completed a $5.5 million fundraising round.

The firm's diagnostics division holds the rights to MSPrecise, a proprietary next-generation sequencing assay for identifying patients with relapsing-remitting multiple sclerosis at first clinical presentation; an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer's disease; and the intellectual property for NuroPro, a Parkinson's disease diagnostic test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.